NO2014031I2 - En kombinasjon av rilpivirine eller et farmasøytisk akseptabelt salt av rilpivirine, innbefattende hydroklorid-saltet av rilpivirine, samt tenofovir, spesielt tenofovir disoproxil eller tenofovir disoproxil fumarat - Google Patents

En kombinasjon av rilpivirine eller et farmasøytisk akseptabelt salt av rilpivirine, innbefattende hydroklorid-saltet av rilpivirine, samt tenofovir, spesielt tenofovir disoproxil eller tenofovir disoproxil fumarat

Info

Publication number
NO2014031I2
NO2014031I2 NO2014031C NO2014031C NO2014031I2 NO 2014031 I2 NO2014031 I2 NO 2014031I2 NO 2014031 C NO2014031 C NO 2014031C NO 2014031 C NO2014031 C NO 2014031C NO 2014031 I2 NO2014031 I2 NO 2014031I2
Authority
NO
Norway
Prior art keywords
rilpivirine
tenofovir
tenofovir disoproxil
pharmaceutically acceptable
combination
Prior art date
Application number
NO2014031C
Other languages
English (en)
Other versions
NO2014031I1 (no
Original Assignee
Janssen Sciences Ireland Uc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34280181&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO2014031(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Sciences Ireland Uc filed Critical Janssen Sciences Ireland Uc
Publication of NO2014031I2 publication Critical patent/NO2014031I2/no
Publication of NO2014031I1 publication Critical patent/NO2014031I1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
NO2014031C 2003-09-03 2014-12-18 (E)-4-[[4-[[4-(2-cyanoetenyl)-2,6-dimetylfenyl]amino-2-pyrimidinyl]-amino]-benzonitril (Rilpivirie) samt enhver terapeutisk ekvivalent form derav som er beskyttet av det aktuelle patentet så som farmasøytisk akseptable salter av Rilpiverine innbefattende hydrokloridsaltet av Rilpivirine, og Temofovir disproksil (spesielt Tenofovir disproksil fumaratsalt). NO2014031I1 (no)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US49977103P 2003-09-03 2003-09-03
EP03103275 2003-09-03
EP03103319 2003-09-08
EP03103335 2003-09-10
EP03103668 2003-10-02
US50848603P 2003-10-03 2003-10-03
PCT/EP2004/052028 WO2005021001A1 (en) 2003-09-03 2004-09-03 Combinations of a pyrimidine containing nnrti with rt inhibitors

Publications (2)

Publication Number Publication Date
NO2014031I2 true NO2014031I2 (no) 2014-12-18
NO2014031I1 NO2014031I1 (no) 2015-01-05

Family

ID=34280181

Family Applications (5)

Application Number Title Priority Date Filing Date
NO20061374A NO334877B1 (no) 2003-09-03 2006-03-27 Kombinasjoner av et pyrimidin inneholdende NNRTI med RT-inhibitorer
NO2014030C NO2014030I1 (no) 2003-09-03 2014-12-18 (E)-4-[[4-[[4-(2-cyanoetenyl)-2,6-dimetylfenyl]-amino]-2-pyrimidinyl]-amino]-benzonitril("Rilpivirine") samt enhver terapeutisk form derav som er dekket av det aktuelle patentet så som farmasøytisk akseptable salter av Rilpivirie innbefattende hydrokloridsaltet av Rilpivirine, og emtricitabine.
NO2014031C NO2014031I1 (no) 2003-09-03 2014-12-18 (E)-4-[[4-[[4-(2-cyanoetenyl)-2,6-dimetylfenyl]amino-2-pyrimidinyl]-amino]-benzonitril (Rilpivirie) samt enhver terapeutisk ekvivalent form derav som er beskyttet av det aktuelle patentet så som farmasøytisk akseptable salter av Rilpiverine innbefattende hydrokloridsaltet av Rilpivirine, og Temofovir disproksil (spesielt Tenofovir disproksil fumaratsalt).
NO2014032C NO2014032I1 (no) 2003-09-03 2014-12-18 (E)-4-[[4-[[4-(2-cyanoetenyl)-2,6-dimetylfenyl-amino]--2-pyrfmidinyl]-amino]-benzonitril Rilpivirine) samt enhver terapeutisk ekvivalent form derav som er beskyttet av det aktuelle patentet så som farmasøytisk akseptable salter innbefattende hydrokloridsaltet av Rilpiverine; tenofovir og spesielt tenofovirdisproksilfumatat og emtricitabine.
NO2016025C NO2016025I1 (no) 2003-09-03 2016-12-20

Family Applications Before (2)

Application Number Title Priority Date Filing Date
NO20061374A NO334877B1 (no) 2003-09-03 2006-03-27 Kombinasjoner av et pyrimidin inneholdende NNRTI med RT-inhibitorer
NO2014030C NO2014030I1 (no) 2003-09-03 2014-12-18 (E)-4-[[4-[[4-(2-cyanoetenyl)-2,6-dimetylfenyl]-amino]-2-pyrimidinyl]-amino]-benzonitril("Rilpivirine") samt enhver terapeutisk form derav som er dekket av det aktuelle patentet så som farmasøytisk akseptable salter av Rilpivirie innbefattende hydrokloridsaltet av Rilpivirine, og emtricitabine.

Family Applications After (2)

Application Number Title Priority Date Filing Date
NO2014032C NO2014032I1 (no) 2003-09-03 2014-12-18 (E)-4-[[4-[[4-(2-cyanoetenyl)-2,6-dimetylfenyl-amino]--2-pyrfmidinyl]-amino]-benzonitril Rilpivirine) samt enhver terapeutisk ekvivalent form derav som er beskyttet av det aktuelle patentet så som farmasøytisk akseptable salter innbefattende hydrokloridsaltet av Rilpiverine; tenofovir og spesielt tenofovirdisproksilfumatat og emtricitabine.
NO2016025C NO2016025I1 (no) 2003-09-03 2016-12-20

Country Status (25)

Country Link
US (9) US20080200435A1 (no)
EP (1) EP1663240B2 (no)
JP (3) JP5507791B2 (no)
KR (1) KR20060090658A (no)
CN (1) CN101060844B (no)
AP (1) AP2109A (no)
AU (5) AU2004268390B2 (no)
BE (1) BE2015C053I2 (no)
CA (1) CA2537095C (no)
CY (5) CY2015039I1 (no)
FI (1) FI1663240T4 (no)
FR (3) FR15C0071I2 (no)
HK (1) HK1092698A1 (no)
HR (1) HRP20150798T4 (no)
HU (5) HUS1500053I1 (no)
IL (2) IL173438A (no)
LT (2) LTPA2016045I1 (no)
LU (3) LU92853I2 (no)
MX (1) MXPA06002437A (no)
MY (1) MY169670A (no)
NL (2) NL300781I2 (no)
NO (5) NO334877B1 (no)
NZ (1) NZ545306A (no)
PL (1) PL1663240T5 (no)
WO (1) WO2005021001A1 (no)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8101629B2 (en) 2001-08-13 2012-01-24 Janssen Pharmaceutica N.V. Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
MY169670A (en) 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
JO3429B1 (ar) 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
US7638522B2 (en) 2001-08-13 2009-12-29 Janssen Pharmaceutica N.V. Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino] benzonitrile
MXPA05001541A (es) 2002-08-09 2005-04-19 Janssen Pharmaceutica Nv Procedimientos para la preparacion de 4-[[4 -[[4- (2-cianoetenil)- 2, 6-dimetilfenil] amino]-2 -pirimidinil] amino] benzonitrilo.
CA2512319A1 (en) 2003-01-14 2004-08-05 Gilead Sciences, Inc. Compositions and methods for combination antiviral therapy
WO2006024668A1 (en) * 2004-09-02 2006-03-09 Janssen Pharmaceutica N.V. Hydrochloride of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl] amino]benzonitrile
CN101068597B (zh) * 2004-09-02 2012-04-18 詹森药业有限公司 4-((4-((4-(2-氰基乙烯基)-2,6-二甲基苯基)氨基)-2-嘧啶基)氨基)苄腈的富马酸盐
EP1632232B3 (en) * 2004-09-02 2022-03-30 Janssen Pharmaceutica NV Salt of 4[[4-[[4-(2-Cyanoethenyl)-2,6-dimethylphenyl]amino]-2-Pyrimidinyl]amino]benzonitrile
MX2007002594A (es) * 2004-09-02 2007-04-25 Janssen Pharmaceutica Nv Fumarato de 4-((4-((4- (2-cianoetenil)-2, 6-dimetilfenil) amino)-2-pirimidinil) amino) benzonitrilo.
EP1789139B1 (en) * 2004-09-02 2012-03-21 Janssen Pharmaceutica NV Fumarate of 4-((4-((4-(2-cyanoethenyl)-2,6-dimethylphenyl amino -2-pyrimidinyl amino benzonitrile
TWI457136B (zh) * 2005-04-04 2014-10-21 Tibotec Pharm Ltd Ｈｉｖ-感染之預防
TWI471145B (zh) * 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
TWI375560B (en) * 2005-06-13 2012-11-01 Gilead Sciences Inc Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
RU2008128424A (ru) * 2005-12-14 2010-01-20 Сипла Лимитед (In) Фармацевтическая комбинация, включающая нуклеотидный и нуклеозидный ингибиторы обратной транскриптазы (такие как тенофовир и ламивудин) в различных частях дозы
TWI458483B (zh) * 2006-01-20 2014-11-01 Tibotec Pharm Ltd Ｈｉｖ感染之長期治療
US9044509B2 (en) * 2006-02-03 2015-06-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Inhibition of HIV infection through chemoprophylaxis
FR2903312B1 (fr) 2006-07-05 2008-09-26 Univ Aix Marseille Ii Utilisation d'inhibiteurs d'hmg-coa reductase et de farnesyl-pyrophosphate synthase dans la preparation d'un medicament
AR065720A1 (es) * 2007-03-14 2009-06-24 Tibotec Pharm Ltd Polvos para reconstitucion que comprenden rilpivirina dispersos en ciertos polimeros. uso. proceso.
JP5570999B2 (ja) 2008-01-03 2014-08-13 ユニベルシテ デ―マルセイユ 抗ｈｉｖ治療の際に使用される組成物
BRPI0923161B1 (pt) * 2008-12-24 2019-01-15 Janssen R&D Ireland dispositivo implantável de uma peça contendo rilpivirina
BR112012015114B1 (pt) 2009-12-21 2023-01-10 Janssen Sciences Ireland Uc Implante farmacêutico subcutâneo removível degradável para liberação sustentada de um composto ativo
EP3351249A1 (en) 2010-01-27 2018-07-25 VIIV Healthcare Company Antiviral therapy
EP2826466A1 (en) * 2010-11-19 2015-01-21 Gilead Sciences, Inc. Therapeutic compositions comprising rilpivirin hcl and tenofovir disoproxil fumarate
WO2012125993A1 (en) 2011-03-17 2012-09-20 Teva Pharmaceutical Industries Ltd. Solid state forms of rilpivirine base, and rilipivirine salts
WO2013038425A1 (en) * 2011-09-16 2013-03-21 Hetero Research Foundation Rilpivirine hydrochloride
SI3608325T1 (sl) 2012-12-21 2022-09-30 Gilead Sciences, Inc. Policiklične-karbamoilpiridonske spojine in njihova farmacevtska uporaba
JP6621933B2 (ja) 2015-11-09 2019-12-18 ギリアード サイエンシス インコーポレーテッド ヒト免疫不全ウイルスを処置するための治療組成物
KR20190073450A (ko) 2016-10-24 2019-06-26 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 분산성 조성물
WO2018119371A1 (en) * 2016-12-23 2018-06-28 Temple University - Of The Commonwealth System Of Higher Education Anti-flaviviridae activity of anti-retroviral non-nucleoside (nnrtis) and nucleoside reverse transcriptase inhibitors (nnrtis)
US11234981B2 (en) 2017-04-18 2022-02-01 Cipla Limited Combination therapy for use in treating retroviral infections
WO2019021319A1 (en) * 2017-07-27 2019-01-31 Cipla Limited PHARMACEUTICAL COMPOSITIONS
CN115397422A (zh) 2019-11-29 2022-11-25 西皮欧生命科学有限公司 包含利匹韦林的组合物和其用于治疗肿瘤或癌症的用途

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5182111A (en) * 1987-11-17 1993-01-26 Boston University Research Foundation In vivo delivery of active factors by co-cultured cell implants
US5047407A (en) 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
GB8815265D0 (en) 1988-06-27 1988-08-03 Wellcome Found Therapeutic nucleosides
US5368864A (en) * 1988-11-25 1994-11-29 Henning Berlin Gmbh Chemie- Und Pharmawerk Formulation of oxypurinol and/or its alkali and alkaline earth salts
MY104575A (en) 1989-12-22 1994-04-30 The Wellcome Foundation Ltd Therapeutic nucleosides.
WO1992001453A1 (en) 1990-07-19 1992-02-06 Otsuka Pharmaceutical Co., Ltd. Solid preparation
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
AU3124793A (en) * 1991-10-29 1993-06-07 Clover Consolidated, Limited Crosslinkable polysaccharides, polycations and lipids useful for encapsulation and drug release
DK0639971T3 (da) 1992-05-13 2000-03-20 Wellcome Found Terapeutiske kombinationer
JPH06316524A (ja) 1992-09-11 1994-11-15 Naoyuki Inoue 抗エイズウイルス剤
TW401303B (en) 1994-07-01 2000-08-11 Janssen Pharmaceutica Nv Anti-HIV triple combination
IT1281502B1 (it) * 1995-06-13 1998-02-18 Sardinian Antiviral Research C Impiego di un inibitore non nucleosidico della trascrittasi inversa in associazione con inibitori nucleosidici per il trattamento della
US6045829A (en) * 1997-02-13 2000-04-04 Elan Pharma International Limited Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers
ATE296091T1 (de) 1999-09-21 2005-06-15 Skyepharma Canada Inc Oberflächenmodifizierte teilchenförmige zusammensetzungen biologisch aktiver stoffe
US6743446B2 (en) * 1999-12-15 2004-06-01 The Ohio State University Research Foundation Methods for stabilizing biologically active agents encapsulated in biodegradable controlled-release polymers
TW200800298A (en) * 2000-01-27 2008-01-01 Zentaris Ag Compressed microparticles for dry injection
SK12822002A3 (sk) 2000-03-30 2003-02-04 Bristol-Myers Squibb Company Perličky s trvalým uvoľňovaním obsahujúce stavudín
US20040115268A1 (en) * 2000-04-26 2004-06-17 Control Delivery Systems, Inc. Systemic delivery of antiviral agents
DE10050199A1 (de) 2000-10-11 2002-04-25 Ethicon Gmbh Flächiges Implantat mit im Ultraschall detektierbaren Elementen
US20040058956A1 (en) 2000-12-11 2004-03-25 Yohko Akiyama Pharmaceutical composition having an improved water solubility
ATE444060T1 (de) 2001-06-22 2009-10-15 Pfizer Prod Inc Pharmazeutische zusammensetzungen enthaltend dispersionen aus arzneistoffen und neutralen polymeren
JO3429B1 (ar) * 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
MY169670A (en) 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
WO2003043586A2 (en) 2001-11-20 2003-05-30 Advanced Inhalation Research, Inc. Compositions for sustained action product delivery
MXPA05001541A (es) 2002-08-09 2005-04-19 Janssen Pharmaceutica Nv Procedimientos para la preparacion de 4-[[4 -[[4- (2-cianoetenil)- 2, 6-dimetilfenil] amino]-2 -pirimidinil] amino] benzonitrilo.
WO2004022033A1 (en) * 2002-09-04 2004-03-18 Microchips, Inc. Method and device for the controlled delivery of parathyroid hormone
AU2003291457A1 (en) 2002-11-08 2004-06-03 Glaxo Group Limited Pharmaceutical antiviral compositions
AP1927A (en) 2002-11-15 2008-12-10 Tibotec Pharm Ltd Substituted indolepyridinium as anti-infective compounds
AU2002350719A1 (en) 2002-11-29 2004-06-23 Janssen Pharmaceutica N.V. Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base
WO2004069812A1 (en) 2003-02-07 2004-08-19 Janssen Pharmaceutica N.V. Pyrimidine derivatives for the prevention of hiv infection
KR100629771B1 (ko) * 2004-01-27 2006-09-28 씨제이 주식회사 결정성이 감소되거나 무정형화된 올티프라즈의 제조방법
AU2005253957B2 (en) 2004-06-08 2011-08-25 Janssen Pharmaceutica Nv Pharmaceutical compositions
MY191349A (en) 2004-08-27 2022-06-17 Bayer Pharmaceuticals Corp New pharmaceutical compositions for the treatment of hyper-proliferative disorders
WO2006024668A1 (en) 2004-09-02 2006-03-09 Janssen Pharmaceutica N.V. Hydrochloride of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl] amino]benzonitrile
EP1632232B3 (en) 2004-09-02 2022-03-30 Janssen Pharmaceutica NV Salt of 4[[4-[[4-(2-Cyanoethenyl)-2,6-dimethylphenyl]amino]-2-Pyrimidinyl]amino]benzonitrile
KR20130030305A (ko) 2004-11-16 2013-03-26 엘란 파마 인터내셔널 리미티드 주사가능한 나노입자형 올란자핀 제형
TWI457136B (zh) 2005-04-04 2014-10-21 Tibotec Pharm Ltd Ｈｉｖ-感染之預防
TW200710091A (en) 2005-04-11 2007-03-16 Tibotec Pharm Ltd (1,10B-dihydro-2-(aminoalkyl-phenyl)-5H-pyrazolo [1,5-c][1,3]benzoxazin-5-yl)phenyl methanone derivatives as HIV viral replication inhibitors
JP2008538754A (ja) * 2005-04-11 2008-11-06 ザ・ボード・オブ・トラスティーズ・オブ・ザ・レランド・スタンフォード・ジュニア・ユニバーシティ 薬剤を含んだ所定のレイヤパターンを有する複層構造体
WO2006131806A2 (en) 2005-06-07 2006-12-14 Pfizer Products Inc. Multiparticulates comprising low-solubility drugs and carriers that result in rapid drug release
US10532028B2 (en) 2005-07-28 2020-01-14 Isp Investments Llc Method to improve characteristics of spray dried powders and granulated materials, and the products thereby produced
TWI458483B (zh) 2006-01-20 2014-11-01 Tibotec Pharm Ltd Ｈｉｖ感染之長期治療
CA2654115C (en) 2006-06-23 2015-12-22 Tibotec Pharmaceuticals Ltd. Aqueous suspensions of tmc278
US20080081064A1 (en) * 2006-09-28 2008-04-03 Surmodics, Inc. Implantable Medical Device with Apertures for Delivery of Bioactive Agents
AR065720A1 (es) 2007-03-14 2009-06-24 Tibotec Pharm Ltd Polvos para reconstitucion que comprenden rilpivirina dispersos en ciertos polimeros. uso. proceso.
ES2437331T3 (es) 2007-07-12 2014-01-10 Janssen R&D Ireland Forma cristalina de 4-[[4-[[4-(2-cianoetenil)-2,6-dimetilfenil]amino]-2-pirimidinil]amino]benzonitrilo
WO2009046299A2 (en) 2007-10-04 2009-04-09 Boston Scientific Scimed, Inc Implantable drug depot for intrathecal drug delivery system for pain management
EP2358198A4 (en) * 2008-10-24 2012-11-14 Concert Pharmaceuticals Inc HYDROXYETHYLAMINO SULFONAMIDE DERIVATIVES

Also Published As

Publication number Publication date
FI1663240T4 (fi) 2023-04-25
JP2012051915A (ja) 2012-03-15
FR15C0072I2 (fr) 2019-05-17
NO20061374L (no) 2006-03-27
IL173438A0 (en) 2006-06-11
CY2015038I1 (el) 2016-08-31
PL1663240T3 (pl) 2015-10-30
LU92855I2 (fr) 2015-12-21
AU2004268390A1 (en) 2005-03-10
HUS1500052I1 (hu) 2016-03-29
CY2015040I2 (el) 2016-08-31
MXPA06002437A (es) 2006-06-20
NL300781I1 (no) 2016-04-19
AU2011201123A1 (en) 2011-04-07
LU92853I2 (fr) 2015-12-21
AU2016210733B2 (en) 2018-11-08
HUS1500053I1 (hu) 2016-03-29
EP1663240B2 (en) 2023-03-01
IL213104A0 (en) 2011-07-31
HK1092698A1 (en) 2007-02-16
LTC1663240I2 (lt) 2022-05-25
NL300768I1 (no) 2015-12-16
NO2014032I1 (no) 2015-01-05
HUS1500054I1 (hu) 2016-03-29
US20170100398A1 (en) 2017-04-13
US20140349971A1 (en) 2014-11-27
JP5507791B2 (ja) 2014-05-28
NO2014032I2 (no) 2014-12-18
US20180228800A1 (en) 2018-08-16
CY2015039I2 (el) 2016-08-31
NL300781I2 (no) 2016-04-19
HUS1600059I1 (hu) 2017-02-28
US20220008417A1 (en) 2022-01-13
EP1663240B1 (en) 2015-04-22
CY2016048I1 (el) 2017-07-12
CY2015038I2 (el) 2016-08-31
LU92854I2 (fr) 2015-12-21
CN101060844B (zh) 2012-01-04
NO2014030I2 (no) 2014-12-18
JP2007520443A (ja) 2007-07-26
MY169670A (en) 2019-05-08
CY2015040I1 (el) 2016-08-31
WO2005021001A1 (en) 2005-03-10
NO2014031I1 (no) 2015-01-05
US20200171027A1 (en) 2020-06-04
FR15C0071I1 (no) 2015-04-12
HUS1600058I1 (hu) 2017-02-28
EP1663240A1 (en) 2006-06-07
FR15C0073I1 (no) 2015-04-12
CY2016049I2 (el) 2017-07-12
HRP20150798T4 (hr) 2023-06-09
AU2011201123B2 (en) 2013-10-10
NO334877B1 (no) 2014-06-23
FR15C0073I2 (fr) 2016-02-12
CA2537095A1 (en) 2005-03-10
CY2016048I2 (el) 2017-07-12
US20080200435A1 (en) 2008-08-21
US20190216807A1 (en) 2019-07-18
US20100029591A1 (en) 2010-02-04
CY2015039I1 (el) 2016-08-31
AP2109A (en) 2010-02-26
HRP20150798T1 (hr) 2015-09-11
CY2016049I1 (el) 2017-07-12
FR15C0071I2 (fr) 2016-02-12
JP5820045B2 (ja) 2015-11-24
NO2014030I1 (no) 2015-01-05
NL300768I2 (nl) 2023-08-09
NO2016025I1 (no) 2016-12-20
LTPA2016045I1 (lt) 2017-01-10
AU2016210733A1 (en) 2016-08-25
FR15C0072I1 (no) 2015-04-12
LTPA2016044I1 (lt) 2017-01-10
KR20060090658A (ko) 2006-08-14
BE2015C053I2 (no) 2023-12-14
AU2014203484B2 (en) 2016-09-29
AP2006003551A0 (en) 2006-04-30
AU2014203484A1 (en) 2014-07-17
US20150283135A1 (en) 2015-10-08
IL213104A (en) 2016-02-29
NZ545306A (en) 2009-11-27
AU2004268390B2 (en) 2011-03-31
PL1663240T5 (pl) 2024-02-26
US8841310B2 (en) 2014-09-23
CA2537095C (en) 2012-05-29
CN101060844A (zh) 2007-10-24
AU2019200813A1 (en) 2019-02-28
JP2015044839A (ja) 2015-03-12
IL173438A (en) 2012-03-29

Similar Documents

Publication Publication Date Title
NO2014031I2 (no) En kombinasjon av rilpivirine eller et farmasøytisk akseptabelt salt av rilpivirine, innbefattende hydroklorid-saltet av rilpivirine, samt tenofovir, spesielt tenofovir disoproxil eller tenofovir disoproxil fumarat
NO2020007I1 (no) Sitagliptin, eventuelt i form av et farmasøytisk akseptabelt salt
NO2017047I1 (no) Tofacitinib, evt. i form av et farmasøytisk akseptabelt salt, inkludert citratsalt
NO2015016I2 (no) Vorapaxar eller et farmasøytisk akseptabelt salt eller solvat derav
NO2014021I1 (no) Bedaquiline eller et farmasøytisk akseptabelt syre- eller baseaddisjonssalt derav
TWI347199B (en) Extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof
NO2016006I2 (no) Tenofovir alafenamid eller et salt eller sovat derav, speielt tenofovir alafenamid fumarat
NO20032909D0 (no) Glukopyranosyloksypyrazolderivater samt medikamentell anvendelse derav
NO2013004I1 (no) axitinib, valgfritt i form av et farmasøytisk aksentabelt salt
HK1064090A1 (en) Xanthine derivative, production and use thereof asa medicament
HK1093731A1 (en) Sulfoximine-substituted pyrimidines for use as cdk and/or vegf inhibitors, the production thereof and their use as drugs
AU2003253765A8 (en) System and method for locating and notifying a user of a person, place or thing having attributes matching the user's stated prefernces
PL1603915T3 (pl) Podstawione pochodne 8-pirydynylo-dihydrospiro-cykloalkilo-pirymido-1,2-a-pirymidyn-6-onu i 8-pirymidynylo-dihydrospiro-cykloalkilo-pirymido-1,2-a-pirymidyn-6-onu oraz ich zastosowanie przeciwko chorobom neurodegeneracyjnym
DK1736158T3 (da) Anvendel af 1- 4-(5-cyanoindol-3-yl)butyl -4-(2-carbamoylbenzofuran-5-yl)piperazin samt de fysiologiske acceptable salte deraf
ITMI20041901A1 (it) Sensore micromeccanico e procedimento per la fabbricazione di un sensore micromeccanico.
FI20020881A0 (fi) Iskulaite
ZA200504997B (en) Phosphonooxy quinazolin derivatives and their pharmaceutical use
IL164836A0 (en) Phosphonates and derivatives thereof as enhancers of the activity of insecticides
PL369736A1 (en) New medicinal compositions on the basis of anticholinergic agents and egfr kinase inhibitors
AU2003281698A8 (en) 1-phenylpiperidin-3-one derivatives and processes for the preparation thereof
AU2003301758A8 (en) Use of pyrimidine derivates for the manifacture of a medicament for the treatment of hyper-proliferative disorders
EE200300466A (et) Püridoindolooni derivaatide kasutamine ravimite valmistamiseks
FI20021365A0 (fi) Imutela
NO2017066I1 (no) Kombinasjon av rilpivirine-hydroklorid eller terapeutisk ekvivalent derav, tenofovir, spesielt tenofovir disproksil fumarat, og emtricitabine
RU2002103738A (ru) Компонент, обеспечивающий поверхностно-активные свойства композиций-аналогов препаратов для заместительной сурфактантной терапии легочных заболеваний

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: JANSSEN SCIENCES IRELAND UC, IE

MK1K Patent expired